This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 Jul;33(7):669-671.

doi: 10.1016/j.annonc.2022.04.008. Epub 2022 Apr 14.

Sarcopenia and cancer-related inflammation measurements in advanced gastric and junctional cancers-ready for prime time?

S Arulananda¹, E Segelov²

Affiliations

Affiliations

¹ Department of Medical Oncology, Monash Health, Clayton; School of Clinical Sciences, Faculty of Medicine, Monash University, Clayton, Australia.
² Department of Medical Oncology, Monash Health, Clayton; School of Clinical Sciences, Faculty of Medicine, Monash University, Clayton, Australia. Electronic address: eva.segelov@monash.edu.

PMID: 35430371
DOI: 10.1016/j.annonc.2022.04.008

Editorial

Sarcopenia and cancer-related inflammation measurements in advanced gastric and junctional cancers-ready for prime time?

S Arulananda et al. Ann Oncol. 2022 Jul.

. 2022 Jul;33(7):669-671.

doi: 10.1016/j.annonc.2022.04.008. Epub 2022 Apr 14.

Authors

S Arulananda¹, E Segelov²

Affiliations

¹ Department of Medical Oncology, Monash Health, Clayton; School of Clinical Sciences, Faculty of Medicine, Monash University, Clayton, Australia.
² Department of Medical Oncology, Monash Health, Clayton; School of Clinical Sciences, Faculty of Medicine, Monash University, Clayton, Australia. Electronic address: eva.segelov@monash.edu.

PMID: 35430371
DOI: 10.1016/j.annonc.2022.04.008

No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors have declared no conflicts of interest.

Comment on

Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial.
Hacker UT, Hasenclever D, Baber R, Linder N, Busse H, Obermannova R, Zdrazilova-Dubska L, Valik D, Lordick F. Hacker UT, et al. Ann Oncol. 2022 Jul;33(7):685-692. doi: 10.1016/j.annonc.2022.03.274. Epub 2022 Apr 5. Ann Oncol. 2022. PMID: 35395383 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions